Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Bulitta JB, Hope WW, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02307-18. doi: 10.1128/AAC.02307-18. Print 2019 May. Review.

2.
3.

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways.

Skoglund E, Abodakpi H, Rios R, Diaz L, De La Cadena E, Dinh AQ, Ardila J, Miller WR, Munita JM, Arias CA, Tam VH, Tran TT.

Case Rep Infect Dis. 2018 Dec 23;2018:9095203. doi: 10.1155/2018/9095203. eCollection 2018.

4.

A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.

Abodakpi H, Chang KT, Zhou J, Byerly C, Tam VH.

Clin Microbiol Infect. 2019 Jan 18. pii: S1198-743X(19)30007-2. doi: 10.1016/j.cmi.2019.01.003. [Epub ahead of print]

PMID:
30664934
5.

Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.

Phe K, Bowers DR, Babic JT, Tam VH.

Diagn Microbiol Infect Dis. 2019 Apr;93(4):346-348. doi: 10.1016/j.diagmicrobio.2018.10.019. Epub 2018 Nov 9.

PMID:
30522794
6.

Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Abodakpi H, Chang KT, Gao S, Sánchez-Díaz AM, Cantón R, Tam VH.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01906-18. doi: 10.1128/AAC.01906-18. Print 2019 Feb.

PMID:
30530606
7.

Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1.

Wong CL, Fok CK, Tam VH.

Endocrinol Diabetes Metab Case Rep. 2018 Mar 28;2018. pii: 18-0006. doi: 10.1530/EDM-18-0006. eCollection 2018.

8.

Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa.

Tam VH, Pérez C, Ledesma KR, Lewis RE.

Microbiol Immunol. 2018 Apr;62(4):291-294. doi: 10.1111/1348-0421.12581. Epub 2018 Mar 26.

PMID:
29418013
9.

Population Pharmacokinetics of Polymyxin B.

Manchandani P, Thamlikitkul V, Dubrovskaya Y, Babic JT, Lye DC, Lee LS, Tam VH.

Clin Pharmacol Ther. 2018 Sep;104(3):534-538. doi: 10.1002/cpt.981. Epub 2018 Jan 8.

PMID:
29238962
10.

Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital.

Abodakpi H, Chang KT, Sánchez Díaz AM, Cantón R, Lasco TM, Chan K, Sofjan AK, Tam VH.

J Chemother. 2018 Apr;30(2):115-119. doi: 10.1080/1120009X.2017.1399233. Epub 2017 Nov 10.

PMID:
29125052
11.

Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.

Skoglund E, Ledesma KR, Lasco TM, Tam VH.

J Glob Antimicrob Resist. 2017 Dec;11:154-155. doi: 10.1016/j.jgar.2017.10.016. Epub 2017 Oct 31. No abstract available.

PMID:
29101084
12.

Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity.

Babic JT, Manchandani P, Ledesma KR, Tam VH.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01735-17. doi: 10.1128/AAC.01735-17. Print 2017 Nov. No abstract available.

13.

The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques.

Grossman TH, Anderson MS, Christ D, Gooldy M, Henning LN, Heine HS, Kindt MV, Lin W, Siefkas-Patterson K, Radcliff AK, Tam VH, Sutcliffe JA.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00448-17. doi: 10.1128/AAC.00448-17. Print 2017 Aug.

14.

Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.

Singh KV, Tran TT, Nannini EC, Tam VH, Arias CA, Murray BE.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00324-17. doi: 10.1128/AAC.00324-17. Print 2017 Jul.

15.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
16.

The complexity of minocycline serum protein binding.

Zhou J, Tran BT, Tam VH.

J Antimicrob Chemother. 2017 Jun 1;72(6):1632-1634. doi: 10.1093/jac/dkx039.

PMID:
28333250
17.

Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.

Tran TT, Tam VH, Murray BE, Arias CA, Singh KV.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02489-16. doi: 10.1128/AAC.02489-16. Print 2017 Jun.

18.

Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model.

Zhou J, Ledesma KR, Chang KT, Abodakpi H, Gao S, Tam VH.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02371-16. doi: 10.1128/AAC.02371-16. Print 2017 May.

19.

Determining β-lactam exposure threshold to suppress resistance development in Gram-negative bacteria.

Tam VH, Chang KT, Zhou J, Ledesma KR, Phe K, Gao S, Van Bambeke F, Sánchez-Díaz AM, Zamorano L, Oliver A, Cantón R.

J Antimicrob Chemother. 2017 May 1;72(5):1421-1428. doi: 10.1093/jac/dkx001.

PMID:
28158470
20.

Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity.

Manchandani P, Zhou J, Babic JT, Ledesma KR, Truong LD, Tam VH.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02391-16. doi: 10.1128/AAC.02391-16. Print 2017 Apr.

21.

Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.

Tam VH, Sosa C, Liu R, Yao N, Priestley RD.

Int J Pharm. 2016 Dec 30;515(1-2):331-342. doi: 10.1016/j.ijpharm.2016.10.031. Epub 2016 Oct 18. Review.

PMID:
27769885
22.

Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.

Thamlikitkul V, Dubrovskaya Y, Manchandani P, Ngamprasertchai T, Boonyasiri A, Babic JT, Tam VH.

Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01337-16. doi: 10.1128/AAC.01337-16. Print 2017 Jan.

23.

Comparative Pharmacokinetic Profiling of Different Polymyxin B Components.

Manchandani P, Dubrovskaya Y, Gao S, Tam VH.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6980-6982. doi: 10.1128/AAC.00702-16. Print 2016 Nov.

24.

Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study.

Phe K, Shields RK, Tverdek FP, Aitken SL, Guervil DJ, Lam WM, Musgrove RJ, Luce AM, Tam VH.

J Antimicrob Chemother. 2016 Dec;71(12):3585-3587. Epub 2016 Aug 19.

25.

An institutional review of antimicrobial stewardship interventions.

Cao H, Phe K, Laine GA, Russo HR, Putney KS, Tam VH.

J Glob Antimicrob Resist. 2016 Sep;6:75-77. doi: 10.1016/j.jgar.2016.03.006. Epub 2016 May 4.

PMID:
27530844
26.

Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections.

Trad MA, Zhong LH, Llorin RM, Tan SY, Chan M, Archuleta S, Sulaiman Z, Tam VH, Lye DC, Fisher DA.

J Chemother. 2017 Feb;29(1):25-29. doi: 10.1080/1120009X.2016.1158937. Epub 2016 May 30.

PMID:
27239695
27.

Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.

Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1029-34. doi: 10.1128/AAC.02445-15. Print 2016 Feb.

28.

Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia.

Patel TS, Cottreau JM, Hirsch EB, Tam VH.

Diagn Microbiol Infect Dis. 2016 Feb;84(2):155-8. doi: 10.1016/j.diagmicrobio.2015.10.024. Epub 2015 Oct 28.

PMID:
26639227
29.

Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients.

Aitken SL, Zhou J, Ghantoji SS, Kontoyiannis DP, Jones RB, Tam VH, Chemaly RF.

J Antimicrob Chemother. 2016 Mar;71(3):727-30. doi: 10.1093/jac/dkv393. Epub 2015 Nov 26.

PMID:
26612873
30.

Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates.

Zhang D, Wu L, Chow DS, Tam VH, Rios DR.

J Pharm Biomed Anal. 2016 Jan 5;117:227-31. doi: 10.1016/j.jpba.2015.09.003. Epub 2015 Sep 5.

PMID:
26372947
31.

Analytical and functional determination of polymyxin B protein binding in serum.

Abodakpi H, Gohlke J, Chang KT, Chow DS, Tam VH.

Antimicrob Agents Chemother. 2015 Nov;59(11):7121-3. doi: 10.1128/AAC.01815-15. Epub 2015 Aug 31.

32.

Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.

Bowers DR, Cao H, Zhou J, Ledesma KR, Sun D, Lomovskaya O, Tam VH.

Antimicrob Agents Chemother. 2015 May;59(5):2720-5. doi: 10.1128/AAC.04110-14. Epub 2015 Feb 23.

33.

Kidney injury associated with telavancin dosing regimen in an animal model.

Tam VH, Ledesma KR, Bowers DR, Zhou J, Truong LD.

Antimicrob Agents Chemother. 2015 May;59(5):2930-3. doi: 10.1128/AAC.05002-14. Epub 2015 Feb 23.

34.

Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia.

Aitken SL, Altshuler J, Guervil DJ, Hirsch EB, Ostrosky-Zeichner LL, Ericsson CD, Tam VH.

Int J Antimicrob Agents. 2015 May;45(5):541-4. doi: 10.1016/j.ijantimicag.2014.12.018. Epub 2015 Jan 19.

PMID:
25665726
35.

Risk factors for nephrotoxicity onset associated with polymyxin B therapy.

Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH.

J Antimicrob Chemother. 2015;70(6):1903-7. doi: 10.1093/jac/dkv014. Epub 2015 Feb 3.

PMID:
25652747
36.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.

PMID:
25459221
37.

In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus.

Phe K, Dao D, Palmer HR, Tam VH.

Antimicrob Agents Chemother. 2015 Feb;59(2):1370. doi: 10.1128/AAC.04531-14. Epub 2014 Nov 17. No abstract available.

38.

Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.

Zasowski E, Bland CM, Tam VH, Lodise TP.

J Antimicrob Chemother. 2015 Mar;70(3):877-81. doi: 10.1093/jac/dku435. Epub 2014 Nov 6.

PMID:
25381169
39.

Agreement among measurements and estimations of glomerular filtration in children with cancer.

Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW.

Pediatr Blood Cancer. 2015 Jan;62(1):80-4. doi: 10.1002/pbc.25194. Epub 2014 Sep 27.

PMID:
25263332
40.

Reply to "measuring polymyxin uptake by renal tubular cells: is BODIPY-polymyxin B an appropriate probe?".

Abdelraouf K, Tam VH.

Antimicrob Agents Chemother. 2014 Oct;58(10):6339. doi: 10.1128/AAC.03784-14. No abstract available.

41.

Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin.

Phe K, Johnson ML, Palmer HR, Tam VH.

Antimicrob Agents Chemother. 2014 Nov;58(11):6946-8. doi: 10.1128/AAC.03776-14. Epub 2014 Aug 18.

42.

Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child.

Zhang D, Rios DR, Tam VH, Chow DS.

J Pharm Biomed Anal. 2014 Oct;99:67-73. doi: 10.1016/j.jpba.2014.07.001. Epub 2014 Jul 10.

PMID:
25072843
43.

Mathematical model to quantify the effects of risk factors on carbapenem-resistant Acinetobacter baumannii.

Tan MW, Lye DC, Ng TM, Nikolaou M, Tam VH.

Antimicrob Agents Chemother. 2014 Sep;58(9):5239-44. doi: 10.1128/AAC.02791-14. Epub 2014 Jun 23.

44.

A novel mutation in pseudohypoparathyroidism type 1a in a Chinese woman and her son with hypocalcaemia.

Tam VH, Chen SP, Mak CM, Fung LM, Lee CY, Chan AY.

Hong Kong Med J. 2014 Jun;20(3):258-60. doi: 10.12809/hkmj134025.

45.

One-pot Stöber route yields template for Ag@carbon yolk-shell nanostructures.

Liu R, Yeh YW, Tam VH, Qu F, Yao N, Priestley RD.

Chem Commun (Camb). 2014 Aug 21;50(65):9056-9. doi: 10.1039/c4cc02507e.

PMID:
24874809
46.

Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections.

Zhou J, Sulaiman Z, Llorin RM, Hee KH, Lee LS, Lye DC, Fisher DA, Tam VH.

J Antimicrob Chemother. 2014 Sep;69(9):2517-21. doi: 10.1093/jac/dku143. Epub 2014 May 5.

PMID:
24797063
47.

Uptake of polymyxin B into renal cells.

Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH.

Antimicrob Agents Chemother. 2014 Jul;58(7):4200-2. doi: 10.1128/AAC.02557-14. Epub 2014 Apr 14.

48.

An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae.

Hirsch EB, Chang KT, Zucchi PC, Francoeur DN, Ledesma KR, Tam VH, Lasco TM.

J Infect Chemother. 2014 Mar;20(3):224-7. doi: 10.1016/j.jiac.2013.10.011. Epub 2013 Dec 11.

PMID:
24674388
49.

In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.

Phe K, Lee Y, McDaneld PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH.

Antimicrob Agents Chemother. 2014 May;58(5):2740-6. doi: 10.1128/AAC.02476-13. Epub 2014 Feb 24.

50.

Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion.

Ng TM, Lye DC, Chan M, Tam VH.

Int J Antimicrob Agents. 2014 Feb;43(2):197-9. doi: 10.1016/j.ijantimicag.2013.10.007. Epub 2013 Nov 8. No abstract available.

PMID:
24359843

Supplemental Content

Support Center